ArticleInternational forum of allergy & rhinology2026
Extent of Sinus Surgery Is Associated With Disease Control in Biologic Treated Type 2 Dominant CRS.
Article in International forum of allergy & rhinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA greater benefit of biologics is observed after surgery in Type 2 chronic rhinosinusitis with nasal polyps (CRSwNP). However, the extent of surgery remains undefined in many studies. This study evaluated the extent of surgery on disease control in patients receiving biologics for refractory Type 2 dominant CRSwNP.
methodsA cross-sectional study was performed on patients with CRSwNP treated with biologics for ≥ 6 months at a tertiary center. All patients had undergone prior sinus surgery, which included a sphenoethmoidectomy and then extension via Draf I, IIa, IIb, IIc, or III. Disease control was defined as having a SNOT-22 ≤ 30, endoscopic modified Lund-Mackay ≤ 4, and the absence of rescue therapy within 6 months. Comparisons were made across surgical and biologic groups, and logistic regression was used to identify factors associated with disease control.
resultsA total of 159 patients were assessed (age 50.9 ± 12.8 years, 45.3% female). Disease control was achieved in 49.1% of patients. Disease control was greater with extended surgery (Draf III 60.8% [49.7%-70.8%] vs. Draf IIc 68.3% [53.0%-80.4%] vs. Draf IIa 8.7% [2.4%-26.8%] vs. Draf I 0% [0.0%-19.4%]; p < 0.001). The control was similar across biologic types (anti-IL-4αR 63.3% [45.5%-78.1%] vs. anti-IL-5/5R 45.7% [37.3%-54.3%]; p = 0.083). On regression, extended surgery (Draf III + IIc) was associated with disease control (Draf III/IIc vs. Draf IIa/I OR: 110.2 [12.7-14,682.5]) but not biologic type (anti-IL-4αR vs. anti-IL-5/5R OR: 2.2 [0.7-7.2]). However, class switching had already occurred in 15.1% of patients initially treated with anti-IL-5/5R.
conclusionsDisease control was greatest in CRSwNP patients who had both extended sinus surgery and optimized biologic treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.